CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

Henry Ford Health System100 enrolled

Overview

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

GVHD,Acute

Interventions

blood sampleDIAGNOSTIC_TEST

blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients \>18 year old admitted for allo SCT PB for malignant disease.

Locations (1)

Henry Ford Health System

Detroit, Michigan, United States

RECRUITING

Outcomes

Primary Outcomes

predictors of acute GVHD

CXCL9 combined with EASIX can be used as predictors of acute GVHD

Time frame: CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.

Central Contacts

shatha farhan, MD

CONTACT

3137133910 sfarhan1@hfhs.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.